Boston Scientific Narrowing Gap With J&J In European DES Market
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's Taxus stent is on track to claim half of the European drug-eluting stent market from rival and first-mover Johnson & Johnson/Cordis over the next several months, the firm says
You may also be interested in...
J&J Forecasts Quicker EU Conversion To Cypher In Wake Of FDA Sign-Off
U.S. approval of Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent will exert pressure on key European markets to pay for the device despite its significant price premium over conventional coronary stents, the company asserts
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.